A
25.66
1.36 (5.60%)
| Penutupan Terdahulu | 24.30 |
| Buka | 24.60 |
| Jumlah Dagangan | 303,544 |
| Purata Dagangan (3B) | 292,834 |
| Modal Pasaran | 899,453,120 |
| Harga / Buku (P/B) | 5.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 May 2026 |
| EPS Cair (TTM) | -2.30 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.01% |
| Nisbah Semasa (MRQ) | 22.53 |
| Aliran Tunai Operasi (OCF TTM) | -53.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -39.36 M |
| Pulangan Atas Aset (ROA TTM) | -22.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -38.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Alto Neuroscience, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.6
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.5 |
| Purata | 0.63 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 7.48% |
| % Dimiliki oleh Institusi | 77.52% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vestal Point Capital, Lp | 31 Dec 2025 | 2,485,000 |
| Commodore Capital Lp | 31 Dec 2025 | 1,823,196 |
| Perceptive Advisors Llc | 31 Dec 2025 | 1,784,393 |
| Vivo Capital, Llc | 31 Dec 2025 | 1,035,551 |
| 72 Investment Holdings, Llc | 31 Dec 2025 | 667,778 |
| Julat 52 Minggu | ||
| Median | 28.00 (9.12%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 17 Feb 2026 | 28.00 (9.12%) | Beli | 19.26 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |